• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
IMM
Click for more information
0.00% 42.0¢

IMMUTEP LIMITED - Corporate Spotlight

Market Cap $499.3M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare Biotechnology

Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company... Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

No Corporate Spotlight currently available.

(20min delay)
Last
42.0¢ 		Change
0.000(0.00%) 		Mkt cap ! $499.3M
Open High Low Value Volume
42.0¢ 43.0¢ 40.5¢ $1.108M 2.653M

Buyers (Bids)

No. Vol. Price($)
1 24000 41.5¢
 

Sellers (Offers)

Price($) Vol. No.
42.0¢ 101546 47
View Market Depth
Last trade - 16.10pm 02/05/2024 (20 minute delay) ?
Last
42.0¢ 		  Change
0.000 ( 0.90 %)
Open High Low Volume
43.0¢ 43.0¢ 41.0¢ 749406
Last updated 15.59pm 02/05/2024 ?
IMM (ASX) Chart

Top Stories

Carnarvon revs up for revised Dorado Development

The Dorado discovery appears on again, with Carnarvon Energy announcing the JV completing a revision of the project’s design to optimise capital costs and accelerate FID by the end of 2024.
Recharged Prospects: 'Watts' on the horizon for copper & lithium The conversation goes much deeper that this title suggests - it explores everything from projections on aluminium & manganese, to what a Donald Trump government could mean for commodities markets.
Lithium Universe ends the quarter charged up for Quebec Refinery roll-out Lithium Universe has closed off the March quarter with a new Chief Financial Officer and strategically located land anchored for its lithium refinery in Quebec, Canada.
Provident Aurum's off-market bid sends Sihayo shares soaring Small-cap mineral and gold explorer, Sihayo Gold (ASX:SIH) shares have soared, on news that the company has received intentions from Provident Aurum Pte to make an off-market takeover offer to acquire all shares of Sihayo Gold.
Why Princeton Professor rates BlinkLab's autism & ADHD screening app In this interview with Sonia Madigan, Professor Sam Wang of Princeton University discusses the development and potential of BlinkLab's (ASX:BB1) AI-driven smartphone app, designed to screen for autism and ADHD.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.